Detecting Circulating Tumor Cells in Bladder Cancer
Author Information
Author(s): Msaouel Pavlos, Koutsilieris Michael
Primary Institution: National and Kapodistrian University of Athens
Hypothesis
Is circulating tumor cell (CTC) detection a reliable method for diagnosing bladder and urothelial cancers and determining disease stage?
Conclusion
CTC evaluation can confirm tumor diagnosis and identify patients with advanced bladder cancer, but its low sensitivity means it should not be used as an initial screening test.
Supporting Evidence
- CTC detection assays showed an overall sensitivity of 35.1%.
- CTC-positive patients were significantly more likely to have advanced disease (OR, 5.05).
- Specificity of CTC detection was high at 89.4%.
Takeaway
Doctors can find tiny cancer cells in the blood of bladder cancer patients, which helps them know if the cancer is more serious, but this test isn't good enough to be the first one they use.
Methodology
A meta-analysis of studies investigating CTC presence in bladder cancer patients, calculating sensitivity, specificity, and likelihood ratios.
Potential Biases
Variability in study designs and definitions of controls may influence results.
Limitations
The overall sensitivity of CTC detection assays was low, and there was significant heterogeneity among studies.
Participant Demographics
The majority of patients were diagnosed with transitional cell carcinoma, with a mean age of 41 years.
Statistical Information
P-Value
0.0099
Confidence Interval
95%CI, 32.4-38%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website